Internal Microbe Ecology Biotech Seres Eyes $100M IPO
Seres Therapeutics, a microbiome biotech developing therapies to replace beneficial bacteria in the gut, is looking to raise up to $100 million in an initial public offering as it jumps into...To view the full article, register now.
Already a subscriber? Click here to view full article